Table 3.
Target antigen | Vaccine | Age | Coverage of antigen (%) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
At birth | 1 m | 2 m | 3 m | 4 m | 5 m | 6 m | 8 m | 9 m | 18 m | 2 y | 3 y | 4 y | 5 y | 6 y | |||
HepB virus | HepB | 1 | 2 | 3 | 99.2 | ||||||||||||
Mycobacterium tuberculosis | BCG | 1 | 99.7 | ||||||||||||||
Poliomyelitis virus | IPV | 1 | 2 | 99.2 | |||||||||||||
bOPV | 3 | 4 | |||||||||||||||
Diphtheria, tetanus, pertussis | DTaP | 1 | 2 | 3 | 4 | 98.8 | |||||||||||
DT | 5 | ||||||||||||||||
Measles, mumps, rubella | MMR | 1 | 2 | 99.1 | |||||||||||||
Japanese encephalitis virus | JE-L | 1 | 2 | 99.1 | |||||||||||||
JE-I | 1 and 2 | 3 | 4 | ||||||||||||||
Neisseria meningitidis | MPSV-A | 99.6 | |||||||||||||||
MPSV-AC | 3 | 4 | 99.2 | ||||||||||||||
HepA virus | HepA-L | 1 | 99.2 | ||||||||||||||
HepA-I | 1 | 2 | – |
m means months, y means years, – means not applicable
HepB Hepatitis B; BCG Bacillus Calmette-Guérin; IPV Inactivated poliovirus vaccine; bOPV Bivalent oral polio vaccine; DTaP Diphtheria, tetanus, and acellular pertussis; DT Diphtheria, tetanus; MMR Measles, mumps, and rubella; JE-L Live-attenuated Japanese encephalitis vaccine; JE-I Inactivated Japanese encephalitis vaccine; MPSV-A Group A meningococcal polysaccharide vaccine; MPSV-AC Group A and Group C meningococcal polysaccharide vaccine; HepA-L Live-attenuated hepatitis A; HepA-I Inactivated hepatitis A